Post-surgical I-131 treatment of pulmonary metastases from papillary thyroid carcinoma in adults under 45 years old: A report of 20 cases

  • Nguyễn Thành Công Bệnh viện Quân y 175
  • Trần Đặng Ngọc Linh Bệnh viện Ung bướu TP. Hồ Chí Minh
  • Trần Quyết Tiến Trường Đại học Quốc gia TP. Hồ Chí Minh

Main Article Content

Keywords

Papillary thyroid carcinoma, disease free survival, I-131 therapy

Abstract

Objective: To investigate clinical characteristics, results of treatment of 20 patients under 45 years old post-surgical 131-I treatment of pulmonary metastases from papillary thyroid carcinoma. Subject and method: Retrospective study 20 cases (from 18-45 years old) papillary thyroid carcinoma with discovering lung metastasis after total thyroidectomy or subtotal thyroidectomy were treated by I-131 after surgery in HCM Cancer Hospital from 2013 to 2022. Result: 90% of cases had metastatic lymph nodes. Rate of ipsilateral, bilateral lymph nodes metastases were 50% and 40% respectively. 20% of total patients need to surgical lymph nodes dissection second time. Tumors with size under 4cm takes 60% and 85% of tumor had extracapsule and infiltrate extra gland. 75% patients had been treated over total dosage of 1000mCi I-131. Conclusion: 70% of patients structure incomplete response and 5% response biochemistry imcompletely. There are not suppresion of the bone marrow.

Article Details

References

1. Nguyễn Mạnh Quốc, Vũ Văn Vũ và Nguyễn Chấn Hùng (2004) Dịch tễ học và ghi nhận ung thư. Trong Nguyễn Chấn Hùng, Ung Bướu học nội khoa, Nhà xuất bản Y học, tr. 15-20.
2. ATA (American Thyroid Association) (2016) American thyroid association management guideline for adult patients with nodules and differentiated thyrod cancer. Thyroid 26(1): 46-52.
3. Doi Sa, Woodhouse NJ (2000) Ablation of thyroid remnant and I-131 dose in differentiated thyroid cancer. Clin Endocrinology 52(6): 756-773.
4. European Thyroid Association (2019) Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J 8(5): 227-245.
5. Fallahi B, Adabin K, Majidi M et al (2011) Incidence of second primary malignancies during a longterm surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clinical Nuclear Medicine, volume 36(4): 277-282.
6. Mazzaferri EL, Jhang SM (1994) Longterm impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428.
7. National comprehensive cancer (2023) Thyroid cancer treatment. Vol 2.23.
8. Robbins RJ, Larson SM et al (2003) Treatment of thyroid cancer metastases with I-131 following thyroid hormone withdrawal or recombinant human TSH. Thyroid 3: 702.
9. Sweeney DC, Johnston GS (1995) Radioiodine therapy for thyroid cancer. Endocrinol Metabol Clin North Am 24: 803-839.
10. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med 372: 621-630.